Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
Rather good news IMO...
https://www.thetimes.co.uk/article/blood-test-warns-of-chemotherapy-risks-jxpw6ss9b
They said that they are one of our partners!
PrimeStore MTM to supply safe sample collection kits for COVID-19 testing programmes
https://www.ekfdiagnostics.com/primestore-mtm-evaluated-by-public-health-england-for-sars-cov-2.html
Amongst these commercial partners, EKF is now working with the University of Leicester for its student COVID-19 screening programme, and international molecular diagnostics group, Yourgene Health, to supply kits to their customer base which includes public schools, universities and corporations. Another partner is Source BioScience which provides ISO:15189 laboratory testing services for the NHS and private healthcare.
Dr Sean Sales, Director of Genomic Services, Yourgene Health, explained how PrimeStore MTM has helped them to streamline their workflow and reduce the turnaround time for getting COVID-19 test results out to patients.
http://www.alignresearch.co.uk/cpt-company/yourgene-health/
Yourgene Health
Rapidly growing in the molecular diagnostics market with significant upside potential from further market consolidation and COVID-19 product sales
Yourgene Health is an international molecular diagnostics group which develops & commercialises genetic products & services, mainly in the area of reproductive health. It works in partnership with global leaders in DNA technology to advance diagnostic science & positively impact human health.
My understanding is that individuals will have multiple tests per annum to allow them board planes etc via the Caxton app that will show the individual is Covid-19 free . I can see this being rolled out also to other areas such as restaurants, trains.....
A test to see if you are infectious. These guys must have something special. They obviously know what they are doing as they are making reagents for the Novacyt Covid test.
TW asks; if you had to bet the ranch on any of your companies, which would it be?
AR answer; YOURGENE!
It is now profitable and has more expertises in that company than any other I have been involved with.
The best CEO I have ever worked with (Lyn Rees)
The structure of the company is now amazing, the operation in Taiwan which covers the whole of Asia is run by our largest shareholder / Director Bill Chang and his team.
Technically for Medtech they are ahead of anyone else and so far ahead of the game.
Taiwans population = 26M
Convid-19 cases = 400
Deads = 6
Developments coming out of Taiwan and Manchester is phenomenal
You can listen to the full interview here https://www.sharesconference.com/buy-tickets
Paul Kerr, CEO of Fusion Antibodies, talks about the company's recent placing to raise £3m along with an update around Covid-19 and plans for the rest of the year.
https://www.brrmedia.co.uk/broadcasts/5eb153e931da814c9fc6dbc4/fusion-antibodies-placing-to-raise-3m
288K tests per week.
BOOM for Yourgene!!
The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.
https://www.barchart.com/stocks/quotes/YGEN.LN/opinion
Life Technologies Limited who own 7% of YGEN is a wholly owned subsidiary of Thermo Fisher. I'd be surprise if we are not involved!
https://uk.finance.yahoo.com/news/thermo-fisher-launches-12-billion-072835691.html
Apart from being hugely vulnerable to a bid ourselves, this opens up a big boost to our turnover!
https://www.insidermedia.com/news/national/health-sector-achievements-celebrated-at-awards
Outstanding Achievement Award
Sponsored by Verlingue Insurance Brokers and Employee Benefits
Winner: Yourgene Health
During 2019, Yourgene raised funds and completed the acquisition of Elucigene Diagnostics, adding to its existing non-invasive testing solutions. The teams have now fully integrated and are located at a dingle facility at Citylabs.
without a doubt!
https://www.barchart.com/stocks/quotes/YGEN.LN/opinion
100% BUY
https://bionow.co.uk/news/b5ddfadcd2cb62/diagnosis-companies-triumph-at-the-bionow-awards
Big winners on the night included Yourgene Health, a molecular diagnostics group which develops and commercialises genetic products and services. It scooped both the Bionow Company of the Year and the Bionow Investment Deal of the Year Award. The group works in partnership with global leaders in DNA technology to advance diagnostic science. Headquartered in Manchester, Yourgene Health launched its first oncology product, the Elucigene DPYD assay, this year as it looks to broaden its offering within precision medicine.
Bionow Investment Deal of the Year Sponsored by QIAGEN
Winner: Yourgene Health
Deal: Acquisition of Elucigene a Manchester-based molecular diagnostics manufacturer and developer by Yourgene Health plc
https://www.brrmedia.co.uk/broadcasts-embed/5db1815734a3cf1389e7f82c/?player_only=true
https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/YGEN/14142529.html
https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/YGEN/14142529.htmlourgene Health plc
("Yourgene" or the "Company" or the "Group")
Results for the Year Ended 31 March 2019,
Business Update and Director Change
Manchester, UK - 10 July 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its results for the year ended 31 March 2019, and provides a business update.
Full year results summary:
· Comprehensive profit of £3.4m (2018: £9.6m loss), the first since 2014 IPO, due substantially to benefits of debt restructuring gains but also to improved trading
· Revenues grew 45% to £8.9m (2018: £6.1m)
· Gross profit also grew 45% to £4.6m (2018: £3.2m)
· Administrative expenses before separately disclosed items were held level at £9.0m, despite a £0.3m increase in net development expenditure
· Adjusted EBITDA loss reduced by 29% to £3.1m (2018: £4.4m)
· Operating loss reduced by 44% to £4.8m (2018: £8.6m)
· Cash used in operations reduced to £4.0m (2018: £9.6m)
· Net cash (cash less borrowings) at year-end of £1.0m (2018: £11.9m net debt), prior to post period-end fundraise and associated acquisition of Elucigene Diagnostics ("Elucigene")
Business update:
· After the period-end, in April 2019, the Company completed an equity fundraise, raising gross proceeds of £11.8m and the acquisition of Elucigene for an enterprise value of £8.8m represented by £6.3m cash and £2.9m equity
· Elucigene recently filed its calendar 2018 accounts with revenues of £3.6m and EBITDA of £1.0m (FRS102 basis)
· Integration of the UK operations of Yourgene Health and Elucigene is proceeding well and annualised synergy cost savings of over £0.5m have been identified, many of which have already been implemented
· The two commercial teams are now operating as a combined function and seeking opportunities for cross-selling, co-presenting at marketing events, and have since delivered the Group's first £1m+ revenue months
· Penetration of existing markets is increasing, for example in India and France
· New markets focus includes Japan, where early momentum is building, and the United States, where a diverse pipeline is expected to generate its first revenues in the current financial year
· Development is progressing well for the new IONA® test compatible with the Illumina next generation sequencing platform and the test remains on schedule for launch in early 2020
· The Group's first oncology product is in a soft launch phase with a number of UK and European clinical partners
Corporate update:
· After a review of the Board's composition, it has been agreed that Keng Hsu will step down from the Board from today to improve the balance of Non-executive and Executive directors, and to allow greater focus on his business d
Mother, 33, sues NHS for £200,000 for failing to carry out tests that would have revealed her baby's Down's syndrome and says she would have had an abortion if she had known the truth
https://www.dailymail.co.uk/news/article-7222481/Mother-sues-NHS-200-000-failing-carry-tests-reveal-babys-Downs-syndrome.html